To our knowledge, our study was the first large-scale retrospective cohort study emulating the CREDENCE and DAPA-CKD trials to compare the incidence of anemia between SGLT2 inhibitor use and GLP-1 RA use in patients with T2D and CKD. This evidence concerns the gene SLC5A2 and anemia (phenotype).